Other News

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023

Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in […]

DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced the closing of its previously announced $37.5 million private placement to accredited investors. The Company sold approximately 11.0 million common shares a purchase price of $3.40 per […]

Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023

NEWS PROVIDED BY Anthos Therapeutics → June 26, 2023 07:00 ET Patient-Centric Survey Conducted in Collaboration with StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology, Capturing Effects on Patient Quality of Life More than Half of Patients Reported Needing to Adjust Their […]

UltraSight and EchoNous Partner to Enable More Accessible Cardiac Ultrasound for Patients

New partnership to bring the benefits of cardiac imaging to new healthcare settings NATIONAL HARBOR, Md., June 23, 2023 /PRNewswire/ — Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced a partnership with point-of-care ultrasound innovator EchoNous, to enable more healthcare professionals to perform cardiac ultrasound and help […]

BIOTRONIK Demonstrates Ongoing Commitment to Advancing Scientific Knowledge at HRS

Four studies shown at Heart Rhythm 2023 were generated from BIOTRONIK’s CERTITUDE research program LAKE OSWEGO, Ore., June 23, 2023 /PRNewswire/ — Continuing a history of commitment to furthering research in its field, four studies supported by BIOTRONIK‘s real-world evidence generating research initiative, CERTITUDE, were presented at Heart Rhythm 2023 on May 20th and 21st. The […]

The Montreal Heart Institute Welcomes FDA Approval of Colchicine for the Treatment of Cardiovascular Diseases

MONTREAL, June 23, 2023 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) welcomes the approval by the United States Food and Drug Administration (FDA) of colchicine for cardiovascular prevention. Low-dose colchicine (0.5 mg once daily) is the first approved anti-inflammatory medication to reduce the risk of myocardial infarction (heart attack), […]

scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes

BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small […]

CVRx Set to Join Russell 2000 & 3000 Indexes

MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it is set to join the Russell 2000 Index and the broad-market Russell 3000 Index at […]

Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering

Oak Ridge, TN, June 22, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Maxim Group LLC (“Maxim”), as Representative of several Underwriters of its previously announced secondary public offering have partially exercised their option to purchase an additional 54,339 Option Shares […]

Jubilant Radiopharma Introduces RUBY Mobile Solutions™

MONTREAL–(BUSINESS WIRE)–Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) in mobile settings. RUBY-FILL is used for cardiac PET imaging under rest or pharmacologic stress conditions to […]